Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUIBRON-T/SR vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Treatment of symptoms and prevention of asthma,Treatment of reversible bronchospasm associated with chronic bronchitis and emphysema
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
200-400 mg orally every 12 hours; extended-release tablets. Initial dose 200 mg every 12 hours; may increase by 200 mg daily every 3-7 days based on serum theophylline levels (target 5-15 mcg/m L). Maximum 800 mg/day.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal t1/2: 3-12 hours (adults); 1-9 hours (children); prolonged in cirrhosis (up to 30 hours), heart failure, elderly. Clinical context: Narrow therapeutic index (5-15 mcg/m L); dosing interval adjusted based on t1/2.
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Hepatic via CYP1A2, CYP2E1, and CYP3A4; undergoes N-demethylation and oxidation. Saturable kinetics.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4): 90% to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid). Biliary/fecal: minimal (<5%).
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
~40% bound to albumin. Binding is reversible and non-saturable.
85-90% bound to albumin.
Vd: 0.3-0.7 L/kg (adults); approximates total body water. Increased Vd in premature infants and obesity; decreased in dehydration.
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral: 100% (immediate-release); 90-100% for SR formulations (dose-dependent slightly lower).
Oral: 60-80% (first-pass metabolism reduces bioavailability).
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: use 75% of normal dose, monitor levels. GFR <10 m L/min: use 50% of normal dose, monitor levels. Dose frequency unchanged.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%, monitor levels. Child-Pugh C: reduce dose by 70%, monitor levels. Use immediate-release forms preferred.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
6-12 years: 10-16 mg/kg/day in divided doses every 12 hours (extended-release). 12-16 years: 12-18 mg/kg/day; target serum theophylline 5-15 mcg/m L. Maximum 800 mg/day.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Initiate at lower end of dosing (200-400 mg/day). Monitor serum concentrations due to decreased clearance. Avoid doses >400 mg/day without level monitoring. Titrate cautiously.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
No FDA black box warning.
No FDA boxed warning exists for this combination product.
Seizures may occur at therapeutic levels,Use caution in patients with peptic ulcer, seizure disorders, cardiac arrhythmias,Monitor serum theophylline levels to avoid toxicity,Drug interactions with fluoroquinolones, cimetidine, macrolides, and allopurinol
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to theophylline or any component,History of seizure disorder (relative),Active peptic ulcer disease (relative)
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid charcoal-grilled meats and high-protein, low-carbohydrate diets which can decrease theophylline clearance. Caffeine-containing foods/beverages may potentiate adverse effects. Consistent dietary habits are recommended to maintain stable drug levels.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Theophylline (active ingredient) is not teratogenic in humans. First trimester: No increased risk of major malformations from epidemiological studies. Second/third trimester: No specific fetal risks; however, high maternal serum levels may cause neonatal toxicity (jitteriness, tachycardia) if near term.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Theophylline is excreted into breast milk with M/P ratio approximately 0.6-0.7. Relative infant dose is less than 10% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for irritability or insomnia. Use lowest effective maternal dose.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
During pregnancy, theophylline clearance may decrease by 20-30% in third trimester due to reduced hepatic metabolism and increased volume of distribution. Monitor serum levels frequently and reduce dose by 10-20% if levels exceed therapeutic range; individualize dosing based on clinical response and drug monitoring.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
Quibron-T/SR is a sustained-release theophylline formulation used for asthma and COPD. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L); levels >20 mcg/m L increase toxicity risk. Cimetidine, ciprofloxacin, and erythromycin decrease clearance, requiring dose reduction. Smoking induces metabolism, requiring higher doses. Use with caution in patients with heart failure, hepatic impairment, or fever.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take exactly as prescribed; do not crush or chew sustained-release tablets.,Avoid excessive caffeine intake (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not stop abruptly; tapering may be needed.,Keep regular appointments for blood level monitoring.,Inform all healthcare providers of this medication.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUIBRON-T/SR vs ACCURBRON, answered by our medical review team.
QUIBRON-T/SR is a Xanthine Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUIBRON-T/SR and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUIBRON-T/SR is: 200-400 mg orally every 12 hours; extended-release tablets. Initial dose 200 mg every 12 hours; may increase by 200 mg daily every 3-7 days based on serum theophylline levels (target 5-15 mcg/m L). Maximum 800 mg/day.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUIBRON-T/SR and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUIBRON-T/SR is classified as Category C. Theophylline (active ingredient) is not teratogenic in humans. First trimester: No increased risk of major malformations from epidemiological studies. Second/third trimester: No sp. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.